Italia markets close in 2 hours 47 minutes

FTSE MIB
34.502,36
-322,65(-0,93%)
Dow Jones
39.806,77
-196,82(-0,49%)
Nasdaq
16.794,88
+108,91(+0,65%)
Nikkei 225
38.946,93
-122,75(-0,31%)
Petrolio
78,22
-1,58(-1,98%)
Bitcoin EUR
65.599,73
+4.008,69(+6,51%)

NVCR May 2024 22.500 call

OPR - OPR Prezzo differito. Valuta in USD.

Aggiungi a watchlist

0,0500

-0,1500

(-75,00%)

In data: 11:23AM EDT. Mercato aperto.

GlobeNewswire
Zai Lab and Novocure Announce LUNAR Phase 3 Clinical Trial Demonstrates Statistically Significant and Clinically Meaningful Extension in Overall Survival for Patients with Metastatic Non-Small Cell Lung Cancer After Platinum-Based Therapies
Tumor Treating Fields therapy together with standard of care provided a statistically significant and clinically meaningful 3-month improvement in median overall survival versus standard of care with no added systemic toxicities Tumor Treating Fields therapy together with immune checkpoint inhibitors resulted in an unprecedented 8-month improvement in median overall survival LUNAR is the first phase 3 clinical trial in more than seven years to show a significant extension in overall survival in